Atypical Antipsychotics (Milestones in Drug Therapy) - Tapa dura

 
9783764359485: Atypical Antipsychotics (Milestones in Drug Therapy)

Sinopsis

The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.

"Sinopsis" puede pertenecer a otra edición de este libro.

Reseña del editor

The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill­ ness, it allowed, for the first time, to adequately control the severe hallu­ cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra­ pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro­ longed treatment, represented a major problem in the treatment of schizo­ phrenic patients.

Reseña del editor

The present volume deals with drugs which play an important role in the therapy of schizophrenia. It describes the introduction of the first antipsychotics on the market and the importance of clozapine, a prototype for atypical antipsychotics, for further investigation of other potentially atypical antipsychotics, which may have an important impact on the therapy and especially the well being of schizophrenic patients, and their introduction in clinical practice. The book is written by experts in the field of schizophrenia both from a clinical and preclinical point of view. It is of interest to practising psychiatrists, to neuroscientists working in the pharmaceutical industry and also to medical students.

"Sobre este título" puede pertenecer a otra edición de este libro.

Otras ediciones populares con el mismo título

9783034895712: Atypical Antipsychotics (Milestones in Drug Therapy)

Edición Destacada

ISBN 10:  3034895712 ISBN 13:  9783034895712
Editorial: Birkhäuser, 2012
Tapa blanda